Abstract
Living donors are frequently used for kidney transplantation in the United States. This option offers a superior patient and graft survival over deceased donor transplantation. It is also an excellent solution to close the widening gap between patients awaiting renal transplantation and number of transplants done. Organ Procurement and Transplantation Network (OPTN) has specified the minimum general and kidney-specific requirements for suitability as a living kidney donor. Transplant programs across the United States have specific medical criteria for living donation which may be beyond the minimum specified by OPTN. Although living kidney donation is deemed safe, a thorough evaluation to assess medical suitability, infectious and malignancy transmission risk, and assessment of residual organ reserve in the donor is required. This chapter covers all aspects of medical evaluation of the living kidney donor in detail. In general, most programs are now more willing to accept donors with treated hypertension, obesity, or a history of kidney stones provided that certain conditions are met. Such aspects of medically complex living kidney donors are also presented here. Certain recipient conditions that should prompt genetic testing in related living donor candidates are also discussed. Other OPTN requirements such as psychosocial evaluation of living donors and their follow-up by the donor center are also highlighted.
Abbreviations
- AER:
-
Albumin excretion rate
- AUA:
-
American Urologic Association
- BMI:
-
Body mass index
- CMS:
-
Centers for Medicare and Medicaid Services
- DTAC:
-
Disease Transmission and Advisory Committee
- ESRD:
-
End-stage renal disease
- KDIGO:
-
Kidney Disease Improving Global Outcomes
- NAT:
-
Nucleic acid test
- OPTN:
-
Organ procurement and transplantation network
- PHS:
-
Public Health Service
- SRTR:
-
Scientific Registry of Transplant Recipients
- TBMN:
-
Thin basement membrane nephropathy
- UNOS:
-
United Network for Organ Sharing
- WHO:
-
World Health Organization
References
Audrezet MP, Cornec-Le Gall E, Chen JM et al (2012) Autosomal dominant polycystic kidney disease: comprehensive mutation analysis of PKD1 and PKD2 in 700 unrelated patients. Hum Mutat 33:1239–1250
Boudville N, Prasad GV, Knoll G et al (2006) Meta-analysis: risk for hypertension in living kidney donors. Ann Intern Med 145:185–196
Bu FX, Maga T, Meyer NC, Wang K, Thomas CP et al (2014) Comprehensive genetic analysis of complement and coagulation genes in atypical hemolytic uremic syndrome. J Am Soc Nephrol 25:55–64
Buell JF, Beebe TM, Trofe J et al (2004) Donor transmitted malignancies. Ann Transplant 9:53–56
Chobanian AV, Bakris GL, Black HR et al (2003) Seventh report of the joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 42:1206–1252
Cohen RA, Brown RS (2003) Clinical practice. Microscopic hematuria. N Engl J Med 348:2330–2338
Davis R, Jones JS, Barocas DA et al (2012) Diagnosis, evaluation and follow-up of asymptomatic microhematuria (AMH) in adults: AUA guideline. J Urol 188:2473–2481
Doshi MD, Goggins MO, Li L et al (2013) Medical outcomes in African American live kidney donors: a matched cohort study. Am J Transplant 13:111–118
Glodny B, Unterholzner V, Taferner B et al (2009) Normal kidney size and its influencing factors – a 64-slice MDCT study of 1.040 asymptomatic patients. BMC Urol 9:19
Gracida C, Espinoza R, Cedillo U et al (2003) Kidney transplantation with living donors: nine years of follow-up of 628 living donors. Transplant Proc 35: 946–947
Grams ME, Sang Y, Levey AS, Matsushita K, Ballew S, Chang AR, Chow EK, Kasiske BL, Kovesdy CP, Nadkarni GN, Shalev V, Segev DL, Coresh J, Lentine KL, Garg AX (2016) Chronic kidney disease prognosis consortium. Kidney-failure risk projection for the living kidney-donor candidate. N Engl J Med 374(5): 411–421
Hart TC, Gorry MC, Hart PS et al (2002) Mutations of the UMOD gene are responsible for medullary cystic kidney disease 2 and familial juvenile hyperuricaemic nephropathy. J Med Genet 39:882–892
Heimbach JK, Taler SJ, Prieto M, Cosio FG, Textor SC, Kudva YC, Chow GK, Ishitani MB, Larson TS, Stegall MD (2005) Obesity in living kidney donors: clinical characteristics and outcomes in the era of laparoscopic donor nephrectomy. Am J Transplant 5:1057–1064
HIV transmitted from a living organ donor-New York City, 2009. Am J Transplant 2011; 11:1334–1337
Humar A, Morris M, Blumberg E, Freeman R, Preiksaitis J, Kiberd B, Schweitzer E, Ganz S, Caliendo A, Orlowski JP, Wilson B, Kotton C, Michaels M, Kleinman S, Geier S, Murphy B, Green M, Levi M, Knoll G, Segev D, Brubaker S, Hasz R, Lebovitz DJ, Mulligan D, O’Connor K, Pruett T, Mozes M, Lee I, Delmonico F, Fischer S (2010) Nucleic acid testing (NAT) of organ donors: is the “best” test the right test? A consensus conference report. Am J Transplant 10:889–899
Ibrahim HN, Foley R, Tan L et al (2009) Long-term consequences of kidney donation. N Engl J Med 360:459–469
Jais JP, Knebelmann B, Giatras I et al (2003) X-linked Alport syndrome: natural history and genotype phenotype correlations in girls and women belonging to 195 families: a “European community Alport syndrome concerted action” study. J Am Soc Nephrol 14: 2603–2610
kidney disease improving global outcomes practice guideline on the evaluation and follow-up care of living kidney donors draft document pdf. Nov 2015
Kirby A, Gnirke A, Jaffe DB et al (2013) Mutations causing medullary cystic kidney disease type 1 lie in a large VNTR in MUC1 missed by massively parallel sequencing. Nat Genet 45:299–303
Kuppachi S, Smith RJH, Thomas CP (2015) Evaluation of genetic renal diseases in potential living kidney donors. Curr Transpl Rep 2:1–14
Lentine KL, Lam NN, Axelrod D, Schnitzler MA, Garg AX, Xiao H, Dzebisashvili N, Schold JD, Brennan DC, Randall H, King EA, Segev DL (2016) Perioperative complications after living kidney donation: a National Study. Am J Transplant 16(6): 1848–1857
Levin A, Lamb EJ, White CT et al (2013) Kidney disease: improving global outcomes (KDIGO) CKD work group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 3:1–150
Mandelbrot DA, Pavlakis M, Danovitch GM et al (2007) The medical evaluation of living kidney donors: a survey of US transplant centers. Am J Transplant 7: 2333–2343
Mjoen G, Hallan S, Hartmann A et al (2014) Long-term risks for kidney donors. Kidney Int 86:162–167
Nalesnik MA, Woodle ES, DiMaio JM, Vasudev B, Teperman LW, Covington S, Taranto S, Gockerman JP, Shapiro R, Sharma V, Swinnen LJ, Yoshida A, Ison MG (2011) Donor-transmitted malignancies in organ transplantation: assessment of clinical risk. Am J Transplant 11:1140–1147
Nordén G, Lennerling A, Nyberg G (2000) Low absolute glomerular filtration rate in the living kidney donor: a risk factor for graft loss. Transplantation 70(9): 1360–1362
OPTN (Organ Procurement and Transplantation Network)/UNOS (United Network for Organ Sharing). OPTN policies, policy 14: living donation. http://optn.transplant.hrsa.gov/ContentDocuments/OPTN_Policies.pdf. Accessed on 10 July 2016
OPTN/UNOS (2014) Recognizing seasonal and geographically endemic infections in organ donors: considerations during living donor evaluation. http://optn.transplant.hrsa.gov/media/1138/seasonal_disease_guidance.pdf. Accessed on 24 June 2016
Parsa A, Kao WH, Xie D et al (2013) APOL1 risk variants, race, and progression of chronic kidney disease. N Engl J Med 369:2183–2196
Pascual J, Abramowicz D, Cochat P et al (2014) European renal best practice guideline on the management and evaluation of the kidney donor and recipient. Nefrologia 34:293–301
Pei Y, Obaji J, Dupuis A, Paterson AD, Magistroni R et al (2009) Unified criteria for ultrasonographic diagnosis of ADPKD. J Am Soc Nephrol 20:205–212
Pei Y, Hwang YH, Conklin J, Sundsbak JL, Heyer CM et al (2014) Imaging-based diagnosis of autosomal dominant polycystic kidney disease. J Am Soc Nephrol 26: 746
Penn I (1996) Malignant melanoma in organ allograft recipients. Transplantation 61:274–278
Reeves-Daniel AM, DePalma JA, Bleyer AJ, Rocco MV, Murea M et al (2011) The APOL1 gene and allograft survival after kidney transplantation. Am J Transplant 11:1025–1030
Rossetti S, Consugar MB, Chapman AB, Torres VE, Guay-Woodford LM et al (2007) Comprehensive molecular diagnostics in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 18:2143–2160
Savige J, Gregory M, Gross O et al (2013) Expert guidelines for the management of Alport syndrome and thin basement membrane nephropathy. J Am Soc Nephrol 24:364–375
Scales CD Jr, Smith AC, Hanley JM, Saigal CS (2012) Urologic diseases in America project. Prevalence of kidney stones in the United States. Eur Urol 62(1): 160–165
Seem DL, Lee I, Umscheid CA et al (2013) Excerpt from PHS guideline for reducing HIV, HBV and HCV transmission through organ transplantation. Am J Transplant 13:1953–1962
Segev DL, Muzaale AD, Caffo BS et al (2010) Perioperative mortality and long-term survival following live kidney donation. JAMA 303:959–966
Springberg PD, Garrett LE Jr, Thompson AL Jr, Collins NF, Lordon RE, Robinson RR (1982) Fixed and reproducible orthostatic proteinuria: results of a 20-year follow-up study. Ann Intern Med 97(4):516
Stamatelou KK, Francis ME, Jones CA, Nyberg LM, Curhan GC (2003) Time trends in reported prevalence of kidney stones in the United States: 1976–1994. Kidney Int 63(5):1817
Sutton JM (1990) Evaluation of hematuria in adults. JAMA 263:2475–2480
The British Transplant Society and The Renal Association (2011) The United Kingdom Guidelines for Living Donor Kidney Transplantation, 3rd edn. https://www.bts.org.uk/Documents/Guidelines/Active/UK%20Guidelines%20for%20Living%20Donor %20Kidney%20July%202011.pdf. Accessed 24 June 2016
Thomas CP, Erlandson JC, Edghill EL, Hattersley AT, Stolpen AH (2008) A genetic syndrome of chronic renal failure with multiple renal cysts and early onset diabetes. Kidney Int 74:1094–1099
Vivante A, Afek A, Frenkel-Nir Y et al (2011) Persistent asymptomatic isolated microscopic hematuria in Israeli adolescents and young adults and risk for end-stage renal disease. JAMA 306:729–736
Wang X, Vrtiska TJ, Avula RT et al (2014) Age, kidney function, and risk factors associate differently with cortical and medullary volumes of the kidney. Kidney Int 85:677–685
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG, part of Springer Nature
About this entry
Cite this entry
Singh, P., Francos, G., McCauley, J. (2018). Living Donor Evaluation and Selection. In: Ramirez, C., McCauley, J. (eds) Contemporary Kidney Transplantation. Organ and Tissue Transplantation. Springer, Cham. https://doi.org/10.1007/978-3-319-19617-6_3
Download citation
DOI: https://doi.org/10.1007/978-3-319-19617-6_3
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-19616-9
Online ISBN: 978-3-319-19617-6
eBook Packages: MedicineReference Module Medicine